OBJECTIVE: Analyze the utility and safety of @entity68658 therapy applied with the CRRT monitor. DESIGN: Prospective study of cohorts. SCOPE: Polyvalent ICU in tertiary university hospital with hepatic transplantation program. @entity1 : Thirty one @entity1 : 9 (22.6%) with @entity879 ( @entity879 ) (1 hepatic surgery, 1 primary graft failure, 7 other causes) and 22 (71%) with @entity810 (AoCLF). INTERVENTIONS: For the treatment, the @entity1 with @entity879 are maintained in the ICU but those with AoCLF are admitted for the performance of the different sessions, that are programmed for a duration of at least 15 hours in AoCLF and in @entity879 are maintained continuously, changing the circuit every 24 hours. VARIABLES OF INTEREST: Metabolic control and complications registered in 75 sessions on 31 @entity1 . RESULTS: Urea decrease was 33.5 (29-38%), @entity1011 36 (31-41%), total @entity648 29 (25-33%) and direct @entity648 34 (30-38%). Clearance was slower, but sustained, after the first 4 hours of each session both for @entity1133 (p<0.001) as well as for @entity648 (p<0.05). The hemodynamic parameters improved and the hematological ones were not altered. We detected decrease in platelets (131 to 120x109/L, p<0.01). In 95 of the sessions in which heparin was used and in 6% where @entity4770 was used, we observed mild @entity548 . We cultured albumin of the circuit at the end of the session in 50 occasions and only obtained growth in 3 cases (6%) (2 @entity5938 , 1 @entity5939 ) without signs of contamination in the @entity1 . CONCLUSIONS: The @entity68658 system applied by CRRT monitors provide adequate @entity648 clearance percentages and is safe, even in serious @entity1 . Prolongation of the duration of the sessions was not accompanied by an increase in the risk of infection secondary to the albumin contamination.

[Safety and efficacy of the XXXX therapy applied by continuous renal replacement therapy (CRRT) monitors].

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity1133 :: ('MESH:D014508', 'Chemical') :: ['urea'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity5938 :: ('1282', 'Species') :: ['Staphylococcus epidermidis'] @entity879 :: ('MESH:D017114', 'Disease') :: ['ALF', 'acute liver failure'] @entity648 :: ('MESH:D001663', 'Chemical') :: ['bilirubin'] @entity68658 :: ('4141', 'Gene') :: ['MARS'] @entity4770 :: ('MESH:D011464', 'Chemical') :: ['epoprostenol'] @entity810 :: ('MESH:D058186', 'Disease') :: ['acute-on-chronic failure'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine'] @entity5939 :: ('1283', 'Species') :: ['S. haemolyticus']
@entity68658 :: (4141,Gene) :: ['MARS']
